Mark J. Gergen
Net Worth
Last updated:
What is Mark J. Gergen net worth?
The estimated net worth of Mr. Mark J. Gergen is at least $7,411,766 as of 10 Dec 2024. He owns shares worth $6,213,316 as insider, has earned $561,960 from insider trading and has received compensation worth at least $636,490 in Poseida Therapeutics, Inc..
What is the salary of Mark J. Gergen?
Mr. Mark J. Gergen salary is $636,490 per year as Pres, Chief Bus. Officer & Director in Poseida Therapeutics, Inc..
How old is Mark J. Gergen?
Mr. Mark J. Gergen is 62 years old, born in 1963.
What stocks does Mark J. Gergen currently own?
As insider, Mr. Mark J. Gergen owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Poseida Therapeutics, Inc. (PSTX) | Pres, Chief Bus. Officer & Director | 651,291 | $9.54 | $6,213,316 |
What does Poseida Therapeutics, Inc. do?
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.
Mark J. Gergen insider trading
Poseida Therapeutics, Inc.
Mr. Mark J. Gergen has made 2 insider trades in 2024, according to the Form 4 filled with the SEC.
The largest trade he's ever made was exercising 30,000 units of PSTX stock on 26 Nov 2024. As of 10 Dec 2024 he still owns at least 651,291 units of PSTX stock.
Poseida Therapeutics key executives
Poseida Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Eric M. Ostertag (52) Chief Executive Officer & Director
- Mr. Harry J. Leonhardt (68) Gen. Counsel, Chief Compliance Officer & Corporation Sec.
- Mr. Mark J. Gergen (62) Pres, Chief Bus. Officer & Director